Nature Communications (Jun 2022)
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
- Nawal Al Kaabi,
- Yun Kai Yang,
- Li Fang Du,
- Ke Xu,
- Shuai Shao,
- Yu Liang,
- Yun Kang,
- Ji Guo Su,
- Jing Zhang,
- Tian Yang,
- Salah Hussein,
- Mohamed Saif ElDein,
- Sen Sen Yang,
- Wenwen Lei,
- Xue Jun Gao,
- Zhiwei Jiang,
- Xiangfeng Cong,
- Yao Tan,
- Hui Wang,
- Meng Li,
- Hanadi Mekki Mekki,
- Walid Zaher,
- Sally Mahmoud,
- Xue Zhang,
- Chang Qu,
- Dan Ying Liu,
- Jing Zhang,
- Mengjie Yang,
- Islam Eltantawy,
- Jun Wei Hou,
- Ze Hua Lei,
- Peng Xiao,
- Zhao Nian Wang,
- Jin Liang Yin,
- Xiao Yan Mao,
- Jin Zhang,
- Liang Qu,
- Yun Tao Zhang,
- Xiao Ming Yang,
- Guizhen Wu,
- Qi Ming Li
Affiliations
- Nawal Al Kaabi
- Sheikh Khalifa Medical City, SEHA
- Yun Kai Yang
- China National Biotec Group Company Limited
- Li Fang Du
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Ke Xu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
- Shuai Shao
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Yu Liang
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Yun Kang
- National Engineering Center for New Vaccine Research
- Ji Guo Su
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Jing Zhang
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Tian Yang
- China National Biotec Group Company Limited
- Salah Hussein
- Sheikh Khalifa Medical City, SEHA
- Mohamed Saif ElDein
- Sheikh Khalifa Medical City, SEHA
- Sen Sen Yang
- National Engineering Center for New Vaccine Research
- Wenwen Lei
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
- Xue Jun Gao
- Lanzhou Institute of Biological Products Company Limited
- Zhiwei Jiang
- Beijing Key Tech Statistical Consulting Co., Ltd
- Xiangfeng Cong
- National Engineering Center for New Vaccine Research
- Yao Tan
- National Engineering Center for New Vaccine Research
- Hui Wang
- Beijing Institute of Biological Products Company Limited
- Meng Li
- China National Biotec Group Company Limited
- Hanadi Mekki Mekki
- Union 71
- Walid Zaher
- G42 Healthcare
- Sally Mahmoud
- G42 Healthcare
- Xue Zhang
- China National Biotec Group Company Limited
- Chang Qu
- China National Biotec Group Company Limited
- Dan Ying Liu
- China National Biotec Group Company Limited
- Jing Zhang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
- Mengjie Yang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
- Islam Eltantawy
- G42 Healthcare
- Jun Wei Hou
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Ze Hua Lei
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- Peng Xiao
- G42 Healthcare
- Zhao Nian Wang
- China National Biotec Group Company Limited
- Jin Liang Yin
- China National Biotec Group Company Limited
- Xiao Yan Mao
- Lanzhou Institute of Biological Products Company Limited
- Jin Zhang
- Beijing Institute of Biological Products Company Limited
- Liang Qu
- China National Biotec Group Company Limited
- Yun Tao Zhang
- China National Biotec Group Company Limited
- Xiao Ming Yang
- China National Biotec Group Company Limited
- Guizhen Wu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
- Qi Ming Li
- The Sixth Laboratory, National Vaccine and Serum Institute (NVSI)
- DOI
- https://doi.org/10.1038/s41467-022-31379-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
SARS-CoV-2 variants with immune escape capability highlight the need for the development of cross-neutralising vaccines and regimens. Here, the authors assess the immunogenicity and safety of NVSI-06-08, that integrates antigens from multiple SARS-CoV-2 strains into a single immunogen, as a heterologous booster in adults previously vaccinated with the inactivated vaccine.
